123 related articles for article (PubMed ID: 33548803)
21. Design and synthesis of tetrahydropyridopyrimidine derivatives as dual GPR119 and DPP-4 modulators.
Fang Y; Zhang S; Wu W; Liu Y; Yang J; Li Y; Li M; Dong H; Jin Y; Liu R; Yang Z
Bioorg Chem; 2020 Jan; 94():103390. PubMed ID: 31662212
[TBL] [Abstract][Full Text] [Related]
22. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
23. Discovery of the oxazabicyclo[3.3.1]nonane derivatives as potent and orally active GPR119 agonists.
Dai X; Stamford A; Liu H; Neustadt B; Hao J; Kowalski T; Hawes B; Xu X; Baker H; O'Neill K; Woods M; Tang H; Greenlee W
Bioorg Med Chem Lett; 2015 Nov; 25(22):5291-4. PubMed ID: 26433449
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and evaluation of novel fused pyrimidine derivatives as GPR119 agonists.
Fang Y; Xiong L; Hu J; Zhang S; Xie S; Tu L; Wan Y; Jin Y; Li X; Hu S; Yang Z
Bioorg Chem; 2019 May; 86():103-111. PubMed ID: 30685641
[TBL] [Abstract][Full Text] [Related]
25. Optimization of 2-piperidin-4-yl-acetamides as melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Designing out hERG inhibition.
Berglund S; Egner BJ; Gradén H; Gradén J; Morgan DG; Inghardt T; Giordanetto F
Bioorg Med Chem Lett; 2009 Aug; 19(15):4268-73. PubMed ID: 19500979
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and biological evaluation of novel 7-azaspiro[3.5]nonane derivatives as GPR119 agonists.
Matsuda D; Kawamura M; Kobashi Y; Shiozawa F; Suga Y; Fusegi K; Nishimoto S; Kimura K; Miyoshi M; Takayama N; Kakinuma H; Ohtake N
Bioorg Med Chem; 2018 May; 26(8):1832-1847. PubMed ID: 29486951
[TBL] [Abstract][Full Text] [Related]
27. Discovery of structurally novel, potent and orally efficacious GPR119 agonists.
Alper P; Azimioara M; Cow C; Mutnick D; Nikulin V; Michellys PY; Wang Z; Reding E; Paliotti M; Li J; Bao D; Zoll J; Kim Y; Zimmerman M; Groessel T; Tuntland T; Joseph SB; McNamara P; Seidel HM; Epple R
Bioorg Med Chem Lett; 2014 May; 24(10):2383-7. PubMed ID: 24751443
[TBL] [Abstract][Full Text] [Related]
28. Discovery and optimization of N-(3-(1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yloxy)phenyl)benzenesulfonamides as novel GPR119 agonists.
Yu M; Ken Zhang J; Wang Y; Zhu J; Kayser F; Medina JC; Siegler K; Conn M; Shan B; Grillo MP; Coward P; Jim Liu J
Bioorg Med Chem Lett; 2014 Jan; 24(1):156-60. PubMed ID: 24332491
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and pharmacological evaluation of aminopyrimidine series of 5-HT1A partial agonists.
Dounay AB; Barta NS; Bikker JA; Borosky SA; Campbell BM; Crawford T; Denny L; Evans LM; Gray DL; Lee P; Lenoir EA; Xu W
Bioorg Med Chem Lett; 2009 Feb; 19(4):1159-63. PubMed ID: 19147349
[TBL] [Abstract][Full Text] [Related]
30. β-Cell Inactivation of
Panaro BL; Flock GB; Campbell JE; Beaudry JL; Cao X; Drucker DJ
Diabetes; 2017 Jun; 66(6):1626-1635. PubMed ID: 28254842
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and biological evaluation of aryl N-methoxyamide derivatives as GPR119 agonists.
Jang YK; Lee KM; Jung KY; Kang SK; Pagire SH; Lee JM; Pagire HS; Kim KR; Bae MA; Lee H; Rhee SD; Ahn JH
Bioorg Med Chem Lett; 2017 Aug; 27(16):3909-3914. PubMed ID: 28666737
[TBL] [Abstract][Full Text] [Related]
32. Discovery of novel 5-oxa-2,6-diazaspiro[3.4]oct-6-ene derivatives as potent, selective, and orally available somatostatin receptor subtype 5 (SSTR5) antagonists for treatment of type 2 diabetes mellitus.
Hirose H; Yamasaki T; Ogino M; Mizojiri R; Tamura-Okano Y; Yashiro H; Muraki Y; Nakano Y; Sugama J; Hata A; Iwasaki S; Watanabe M; Maekawa T; Kasai S
Bioorg Med Chem; 2017 Aug; 25(15):4175-4193. PubMed ID: 28642028
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological evaluation of a 6-aminofuro[3,2-c]pyridin-3(2H)-one series of GPR 119 agonists.
Sakairi M; Kogami M; Torii M; Kuno Y; Ohsawa Y; Makino M; Kataoka D; Okamoto R; Miyazawa T; Inoue M; Takahashi N; Harada S; Watanabe N
Arzneimittelforschung; 2012 Nov; 62(11):537-44. PubMed ID: 22972470
[TBL] [Abstract][Full Text] [Related]
34. Discovery of orally active sulfonylphenyl thieno[3,2-d]pyrimidine derivatives as GPR119 agonists.
Kim H; Kim M; Oh K; Lee S; Lim S; Lee S; Kim YH; Suh KH; Min KH
Eur J Med Chem; 2023 Oct; 258():115584. PubMed ID: 37356344
[TBL] [Abstract][Full Text] [Related]
35. Discovery and biological evaluation of novel G protein-coupled receptor 119 agonists for type 2 diabetes.
Zhou Y; Wang Y; Zhang L; Tang C; Feng B
Arch Pharm (Weinheim); 2019 Apr; 352(4):e1800267. PubMed ID: 30740769
[TBL] [Abstract][Full Text] [Related]
36. Discovery and optimization of 5-(2-((1-(phenylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)oxy)pyridin-4-yl)-1,2,4-oxadiazoles as novel gpr119 agonists.
Wang Y; Yu M; Zhu J; Zhang JK; Kayser F; Medina JC; Siegler K; Conn M; Shan B; Grillo MP; Liu JJ; Coward P
Bioorg Med Chem Lett; 2014 Feb; 24(4):1133-7. PubMed ID: 24440299
[TBL] [Abstract][Full Text] [Related]
37. Novel tricyclic pyrazolopyrimidines as potent and selective GPR119 agonists.
Azimioara M; Alper P; Cow C; Mutnick D; Nikulin V; Lelais G; Mecom J; McNeill M; Michellys PY; Wang Z; Reding E; Paliotti M; Li J; Bao D; Zoll J; Kim Y; Zimmerman M; Groessl T; Tuntland T; Joseph SB; McNamara P; Seidel HM; Epple R
Bioorg Med Chem Lett; 2014 Dec; 24(23):5478-83. PubMed ID: 25455488
[TBL] [Abstract][Full Text] [Related]
38. Circumventing seizure activity in a series of G protein coupled receptor 119 (GPR119) agonists.
Scott JS; Bowker SS; Brocklehurst KJ; Brown HS; Clarke DS; Easter A; Ertan A; Goldberg K; Hudson JA; Kavanagh S; Laber D; Leach AG; MacFaul PA; Martin EA; McKerrecher D; Schofield P; Svensson PH; Teague J
J Med Chem; 2014 Nov; 57(21):8984-98. PubMed ID: 25286150
[TBL] [Abstract][Full Text] [Related]
39. Optimization of a series of 2,4-diaminopyridines as neuropeptide Y Y1 receptor antagonists with reduced hERG activity.
Kameda M; Kobayashi K; Ito H; Miyazoe H; Tsujino T; Nakama C; Kawamoto H; Ando M; Ito S; Suzuki T; Kanno T; Tanaka T; Tahara Y; Tani T; Tanaka S; Tokita S; Sato N
Bioorg Med Chem Lett; 2009 Aug; 19(15):4325-9. PubMed ID: 19487123
[TBL] [Abstract][Full Text] [Related]
40. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release.
Chu ZL; Carroll C; Alfonso J; Gutierrez V; He H; Lucman A; Pedraza M; Mondala H; Gao H; Bagnol D; Chen R; Jones RM; Behan DP; Leonard J
Endocrinology; 2008 May; 149(5):2038-47. PubMed ID: 18202141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
